The National Institutes of Health has expanded the All of Us Research Program's curated dataset to more than 747,000 participants, its largest data release to date.

The ninth curated repository includes more than 535,000 whole-genome sequences linked with nearly 482,000 electronic health records. NIH describes that combination as the world's largest integrated genomic and EHR database.

Graphic lists 747,028 participants, more than 535,000 genomes and nearly 482,000 health records.
CDRv9 includes data from 747,028 participants, more than 535,000 whole genomes and nearly 482,000 electronic health records.Boho News graphic from cited primary dataView source

The controlled-tier characterization report gives an exact participant count of 747,028, an increase of 17.91% from the prior release's 633,547 participants.

The release also moves the program into multiomics. It includes proteomics data from nearly 10,000 participants, RNA-sequencing data from nearly 9,000 and long-read whole genomes from more than 14,500.

NIH reported more than 1.3 billion genetic variants, 553,000 genotyping arrays, 96,000 structural-variant records and 600,000 physical measurements in the broader release.

More than 645,000 people in the dataset, 86% of the total, come from communities NIH classifies as historically underrepresented in biomedical research. Participants span all 50 states and territories.

Graphic lists proteomics, RNA sequencing and long-read genome counts in the new release.
The release adds nearly 10,000 proteomics records, nearly 9,000 RNA-sequencing records and more than 14,500 long-read genomes.Boho News graphic from cited primary dataView source

Registered researchers can use the cloud-based Researcher Workbench without a data-access fee, although computing and controlled-tier governance requirements still shape practical access.

Scale does not eliminate bias or missingness. The characterization report explicitly tells researchers to consider completeness, data sources and limits on generalizing findings to populations not represented in the same way.

The release is research infrastructure, not a clinical test or treatment. Its value will depend on reproducible studies, careful privacy controls and validation of discoveries in independent populations before clinical use.